Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes.

[1]  Peter H Gann,et al.  Prostate specific antigen best practice statement: 2009 update. , 2009, The Journal of urology.

[2]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[3]  R. Nelson,et al.  The impact of prostate gland weight in robot assisted laparoscopic radical prostatectomy. , 2008, The Journal of urology.

[4]  R. Miralbell,et al.  Recent trends in prostate cancer mortality show a continuous decrease in several countries , 2008, International journal of cancer.

[5]  L. Ferrucci,et al.  Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. , 2006, Journal of the National Cancer Institute.

[6]  W. Catalona,et al.  Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. , 2006, The Journal of urology.

[7]  Liang Cheng,et al.  Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer , 2005, Modern Pathology.

[8]  William J Catalona,et al.  The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA , 2004, BJU international.

[9]  Rosalie Nolley,et al.  The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? , 2004, The Journal of urology.

[10]  Ming-Hui Chen,et al.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2004, The New England journal of medicine.

[11]  P. Humphrey,et al.  Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. , 2002, Urology.

[12]  T. Stamey.  Preoperative serum prostate-specific antigen (PSA) below 10 microg/l predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure. , 2001, Clinical chemistry.

[13]  P. Humphrey,et al.  Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy , 2000, Cancer.

[14]  T. Stamey,et al.  Assessment of morphometric measurements of prostate carcinoma volume , 2000, Cancer.

[15]  M E Hammond,et al.  Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland: a basis for checklists. Cancer Committee. , 2000, Archives of pathology & laboratory medicine.

[16]  T. Stamey,et al.  Biological determinants of cancer progression in men with prostate cancer. , 1999, JAMA.

[17]  P. Humphrey,et al.  Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. , 1998, Urology.

[18]  R T Vollmer,et al.  Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[19]  D. Bostwick,et al.  Recommendations for the reporting of resected prostate carcinomas , 1997, Human pathology.

[20]  D. Bostwick,et al.  Recommendations for the reporting of resected prostate carcinomas. Association of Directors of Anatomic and Surgical Pathology. , 1996, American journal of clinical pathology.

[21]  P. Troncoso,et al.  Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. , 1995, The Journal of urology.

[22]  T. Stamey,et al.  The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. , 1994, The Journal of urology.

[23]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[24]  A W Partin,et al.  Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. , 1993, The Journal of urology.

[25]  A S Whittemore,et al.  Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer , 1993, Cancer.

[26]  A. Rademaker,et al.  Re: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. , 1990, The Journal of urology.

[27]  T. Stamey,et al.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. , 1989, The Journal of urology.

[28]  K. E. Corrigan,et al.  Detection of concealed thyroid disease by tracer technique. , 1953, Journal of the American Medical Association.

[29]  O. Brawley,et al.  Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening , 2009, CA: a cancer journal for clinicians.

[30]  William J Catalona,et al.  Accuracy of prostate weight estimation by digital rectal examination versus transrectal ultrasonography. , 2005, The Journal of urology.

[31]  A. Hoznek,et al.  Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. , 2003, European urology.

[32]  T. Stamey,et al.  Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients. , 1996, The Journal of urology.